Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$8.4B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing drugs that treat various disorders related to cortisol, a stress hormone. With a market cap of $8 billion, the company plays a significant role in the healthcare sector, particularly in addressing conditions like Cushing's syndrome and other diseases linked to cortisol dysregulation.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing no revenue figures. The stock experienced a slight decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Corcept's upcoming earnings are mixed, with no analyst estimates available. The market is uncertain about the company's revenue trajectory and profitability.

Bull Case

If Corcept can demonstrate strong revenue growth and improved EPS, it could signal a positive trend in its business operations and attract more investor interest.

Bear Case

Conversely, if the company fails to show any revenue growth or continues to report losses, it may lead to further declines in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2-2026?

Revenue is critical for assessing the company's growth potential and overall financial health, especially after a quarter with no reported revenue.

What guidance can management provide for future quarters?

Any forward-looking statements from management will be crucial for investor sentiment and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Corcept's potential for revenue growth, given its focus on cortisol-related disorders, which are increasingly recognized in the healthcare sector.

Supporting Evidence

The options market is pricing a 20.58% move, indicating significant uncertainty that may not reflect the company's actual performance.

Corcept has a history of surprising investors with its revenue potential, as seen in previous quarters where it exceeded expectations.

Key Risk

If revenue comes in above $10 million, it could challenge the current cautious sentiment and shift the narrative around the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently divided on Corcept's ability to generate revenue, making this earnings report a pivotal moment for the company's future.

Bull Confirmed If

A revenue figure exceeding $10 million would confirm strong demand for Corcept's products and support a bullish outlook.

Bear Confirmed If

If revenue falls below $5 million, it would raise serious concerns about the company's growth prospects and confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move of over 20%, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations and raises guidance, history suggests the stock could rise by around 2.74%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see minimal movement as investors reassess their outlook.

Miss

A miss on earnings could lead to a decline of approximately 0.61%, as historical patterns indicate negative reactions to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Details on sales performance in key markets.
3Management's commentary on competitive pressures in the pharmaceutical industry.
4Insights into operational efficiencies and cost management strategies.
5Any changes in regulatory environment affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing no revenue figures. The stock experienced a slight decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Corcept's upcoming earnings are mixed, with no analyst estimates available. The market is uncertain about the company's revenue trajectory and profitability.

Bull Case

If Corcept can demonstrate strong revenue growth and improved EPS, it could signal a positive trend in its business operations and attract more investor interest.

Bear Case

Conversely, if the company fails to show any revenue growth or continues to report losses, it may lead to further declines in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue figure for Q2-2026?

Revenue is critical for assessing the company's growth potential and overall financial health, especially after a quarter with no reported revenue.

What guidance can management provide for future quarters?

Any forward-looking statements from management will be crucial for investor sentiment and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Corcept's potential for revenue growth, given its focus on cortisol-related disorders, which are increasingly recognized in the healthcare sector.

Supporting Evidence

The options market is pricing a 20.58% move, indicating significant uncertainty that may not reflect the company's actual performance.

Corcept has a history of surprising investors with its revenue potential, as seen in previous quarters where it exceeded expectations.

Key Risk

If revenue comes in above $10 million, it could challenge the current cautious sentiment and shift the narrative around the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently divided on Corcept's ability to generate revenue, making this earnings report a pivotal moment for the company's future.

Bull Confirmed If

A revenue figure exceeding $10 million would confirm strong demand for Corcept's products and support a bullish outlook.

Bear Confirmed If

If revenue falls below $5 million, it would raise serious concerns about the company's growth prospects and confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move of over 20%, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations and raises guidance, history suggests the stock could rise by around 2.74%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see minimal movement as investors reassess their outlook.

Miss

A miss on earnings could lead to a decline of approximately 0.61%, as historical patterns indicate negative reactions to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Details on sales performance in key markets.
3Management's commentary on competitive pressures in the pharmaceutical industry.
4Insights into operational efficiencies and cost management strategies.
5Any changes in regulatory environment affecting product approvals.